Company news
Tyra Biosciences, Inc. (NASDAQ:TYRA) news
Tyra Biosciences, Inc. news releases on 6ix. Latest, Mar 1, 2023: Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent…
Press releases — page 2
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
February 28, 2023
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
November 28, 2022
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
November 2, 2022
Tyra Biosciences Announces Planned Chief Financial Officer Transition
November 1, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022
Tyra Biosciences to Participate at September 2022 Investor Conferences
September 7, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
September 4, 2022
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
August 3, 2022
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
May 4, 2022
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
March 2, 2022
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
February 21, 2022
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
November 9, 2021
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights
November 2, 2021
Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 16, 2021
Tyra Announces Pricing of Upsized Initial Public Offering
September 13, 2021